Hydrochloric Acid

Hydrochloric Acid

SCHEMBL288029

Cl.Cl.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 4/20 0.63
ESR2 known ✓ Q92731 4/20 0.63
GAA known ✓ P10253 1/20 0.48
DRD1 known ✓ P21728 2/20 0.35
CA2 known ✓ P00918 2/20 0.33
GLA known ✓ P06280 1/20 0.33
ACHE known ✓ P22303 1/20 0.33
TDP1 Q9NUW8 3/20 0.92
CYP3A4 P08684 1/20 0.92
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 4/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
LMNA P02545 2/20 0.33
CA12 O43570 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28613396 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL8372285 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL28386435 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Benzene SCHEMBL11521546 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL7930992 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL1584554 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL288031 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL447754 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL9414432 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Hydrochloric Acid SCHEMBL7786619 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114522704-B Ruthenium/phosphorus catalyst and preparation method and application thereof 湖北中科墨磷科技有限公司 2024-11-15 CN claimed
CN-117986595-B Macromolecular poly-plasticizer and preparation method thereof 揭阳市奥尔康鞋业有限公司 2024-09-20 CN claimed
US-20240246990-A1 PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) CELGENE INTERNATIONAL II SARL (CH) 2024-07-25 US claimed
CN-116573994-B Direct cross-coupling method of triazine ester and aryl bromide 南京工业大学 2024-06-14 CN claimed
CN-118027028-A AZ191 intermediate, preparation method and preparation method of AZ191 上海凌凯医药科技有限公司 2024-05-14 CN claimed
CN-117986595-A Macromolecular poly-plasticizer and preparation method thereof 揭阳市奥尔康鞋业有限公司 2024-05-07 CN claimed
CN-113336717-B Process for preparing oxazolecarboxylic acid esters 江西天新药业股份有限公司 2024-04-05 CN claimed
WO-2024054548-A1 POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS PROMERUS, LLC (US) 2024-03-14 WO claimed
EP-4237461-A1 SHELF LIFE STABLE AND IMPROVED MASS POLYMERIZABLE POLYCYCLIC-OLEFINIC COMPOSITIONS Promerus, LLC (US) 2023-09-06 EP claimed
EP-4237460-A1 POLYCYCLIC-OLEFINIC COMPOSITIONS FOR LOW-LOSS FILMS HAVING IMPROVED THERMAL PROPERTIES Promerus, LLC (US) 2023-09-06 EP claimed
EP-0386973-A2 Preparation process of thermoplastic resin composite MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-09-12 EP claimed
EP-0040741-B1 PROCESS FOR THE PREPARATION OF CHLOROFORMIC-ACID ARYL ESTERS BAYER AG (DE) 1983-06-08 EP claimed
US-4366102-A Process for the preparation of chloroformic acid aryl esters BAYER AKTIENGESELLSCHAFT (DE) 1982-12-28 US claimed
US-4301301-A BY HYDROGENATION OF TRIPHENYLPHOSPHINE DIHALIDE IN A MONO- OR DICHLOROBENZENE SOLVENT UBE INDUSTRIES, LTD. (JP) 1981-11-17 US claimed
EP-0005746-B1 PROCESS FOR PREPARING TRIPHENYL PHOSPHINE F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-08-05 EP claimed
EP-0005747-B1 PROCESS FOR PREPARING TRIPHENYL PHOSPHINE F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-06-10 EP claimed
US-4249023-A Process for manufacturing triphenylphosphine HOFFMANN-LA ROCHE INC. (US) 1981-02-03 US claimed
US-4246204-A Process for manufacturing triphenylphosphine HOFFMANN-LA ROCHE INC. (US) 1981-01-20 US claimed
US-4044060-A PHOSGENE, THIONYL, PHOSPHORUS, ALDEHYDE, KETONE BAYER AKTIENGESELLSCHAFT (DT) 1977-08-23 US claimed
US-3981919-A Racemization of optically active allethrolone SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-09-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246990-A1 PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) PSMA5, EPOR, CYP8B1 ESR1 3002/4885ESR2 2117/4885GAA 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.